Jubilant Therapeutics Reveals Rapid Platelet Reduction with JBI-802 in Phase 1 Clinical Study at 68th ASH Annual Meeting
Preliminary data show all 15 mg dosage patients achieve significant platelet decline by Week 3; company to host detailed event on December 14, 2026
Jubilant Therapeutics reports preliminary Phase 1 clinical data of JBI-802, a first-in-class oral dual LSD1/HDAC6 inhibitor, showing rapid platelet reduction and durable hematologic control in patients with essential thrombocythemia and related myeloproliferative neoplasms. Data presented at the 68th American Society of Hematology Annual Meeting highlight safety and early efficacy with notable platelet normalization by Week 3.
Jubilant Therapeutics Inc.
New Ventures
Jubilant Therapeutics announced the oral presentation of preliminary Phase 1 clinical data for JBI-802, an oral dual LSD1/HDAC6 inhibitor, demonstrating rapid platelet reductions and durable hematologic control in essential thrombocythemia and related myeloproliferative neoplasms. The data highlight safety and early efficacy from their ongoing Phase 1/2 study featured at the 68th American Society of Hematology Annual Meeting.
The Phase 1/2 open-label multicenter trial evaluates JBI-802’s safety, tolerability, and preliminary efficacy in patients with essential thrombocythemia, polycythemia vera, and related myelodysplastic/myeloproliferative neoplasms with thrombocytosis who have relapsed, are refractory, or intolerant to standard care.
Key findings from 8 patients receiving the 15 mg dose include over 50% platelet reduction or platelet normalization (<400 ×10⁹/L) by Week 3, with a median response time of 15 days. Platelet normalization persisted for up to 46 weeks in patients with more than 12 weeks of follow-up.
Additionally, 7 of 11 patients with leukocytosis treated at 15 mg achieved complete hematologic responses. No dose-limiting toxicities were observed at doses of 5, 7, or 15 mg.
Jubilant Therapeutics plans an event on December 14, 2026, to discuss Phase 1 data and clinical implications, coinciding with the oral presentation at ASH. Further detailed efficacy, safety, and molecular data will be shared during the session.
JBI-802 targets the CoREST complex by dual inhibition of LSD1 and HDAC6, impacting disease-relevant cellular processes including abnormal megakaryocyte differentiation, platelet production, leukocyte proliferation, and inflammatory signaling.
Highlights
- Phase 1 data presented at 68th ASH Annual Meeting, December 12–15, 2026 in New Orleans and online.
- All 8 patients at 15 mg dose achieved >50% platelet reduction or normalization by Week 3.
- Platelet normalization maintained up to 46 weeks in patients with >12 weeks follow-up.
- No dose-limiting toxicities reported at doses 5, 7, or 15 mg.
- Seven of 11 patients with leukocytosis achieved complete hematologic response.
- Jubilant to hold webcast event December 14, 2026, to review clinical data and implications.
Key Data Snapshot
What happened
- Jubilant Therapeutics presented preliminary Phase 1 clinical data of JBI-802 at the 68th American Society of Hematology Annual Meeting.
- The data demonstrate rapid platelet reduction and durable hematologic control in essential thrombocythemia and related myeloproliferative neoplasms.
- JBI-802 is an oral dual LSD1/HDAC6 inhibitor targeting the CoREST complex.
Key details
- The Phase 1/2 trial enrolled patients with myeloproliferative neoplasms who were relapsed, refractory, or intolerant to standard care.
- At 15 mg dose, all patients achieved significant platelet reduction or normalization by Week 3.
- Platelet normalization was maintained in patients for up to 46 weeks at follow-up.
- Seven of 11 patients with leukocytosis achieved complete hematologic responses.
- No dose-limiting toxicities were reported at 5, 7, or 15 mg doses.
Order and execution details
- The oral presentation is scheduled for December 14, 2026, during the ASH Annual Meeting.
- Jubilant Therapeutics will host a live webcast event on December 14, 2026, to discuss data and implications.
- Further efficacy, safety, and molecular data will be shared in oral and poster presentations at the meeting.
Background and context
- JBI-802 inhibits LSD1 and HDAC6 enzymes, impacting processes linked to disease progression.
- It is being evaluated specifically for essential thrombocythemia, polycythemia vera, and related myeloproliferative disorders.
- Jubilant Therapeutics is a clinical-stage biopharmaceutical company focused on precision therapies for myeloproliferative neoplasms.
Highlights
- Phase 1 data presented at 68th ASH Annual Meeting, December 12–15, 2026 in New Orleans and online.
- All 8 patients at 15 mg dose achieved >50% platelet reduction or normalization by Week 3.
- Platelet normalization maintained up to 46 weeks in patients with >12 weeks follow-up.
- No dose-limiting toxicities reported at doses 5, 7, or 15 mg.
- Seven of 11 patients with leukocytosis achieved complete hematologic response.
- Jubilant to hold webcast event December 14, 2026, to review clinical data and implications.
Disclosures
- Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on New Ventures
View allLatest corporate announcements and market updates in New Ventures.
Prestige Estates Launches 260-Unit Prestige Avon Residential Project on Thanisandra Main Road, Bengaluru
Prestige Estates Projects Limited has announced the launch of Prestige Avon, a premium residential development consisting of 260 apartments on Thanisandra Main Road in North Bengaluru, featuring 2 and 3 BHK homes including select layouts with home offices.
Read Full StorySignatureGlobal Acquires 10.18 Acres in Sohna, Gurugram to Expand Real Estate Development Portfolio
SignatureGlobal (India) Limited and its wholly owned subsidiary SignatureGlobal Business Park Limited have entered into collaboration agreements to develop approximately 10.18 acres of land in Sohna, Gurugram, Haryana, expanding their land bank and development capacity.
Read Full StoryFirstsource and SEW.AI Introduce AI-Powered Smart Revenue Solutions for Energy and Water Utilities
Firstsource Solutions has partnered with SEW.AI to launch Smart Revenue Operations and Smart Revenue Collections, AI-driven solutions designed to optimize billing and cash collections for energy and water utilities.
Read Full Story